Table 3.
Phenotypic properties of patient-derived gp160s
| gp160a | Sample material | Coreceptor usage | Propertyb |
||||
|---|---|---|---|---|---|---|---|
| Macrophage tropism | Maraviroc sensitivity | sCD4 sensitivity | b12 sensitivity | 2G12 sensitivity | |||
| E21LnD4 | Lymph node | CCR5 | – | + | ++ | +++ | +++ |
| E21LnD10 | Lymph node | CCR5 | – | ++ | ++ | +++ | +++ |
| E21LnD17 | Lymph node | CCR5 | – | + | ++ | +++ | +++ |
| E21LnD24 | Lymph node | CCR5 | – | ++ | +++ | +++ | ++ |
| E21LnD43 | Lymph node | CXCR4 | – | – | + | ++ | ++ |
| E21LnD58 | Lymph node | CCR5 | – | + | + | +++ | +++ |
| E21BrD2 | Brain | CCR5 | ++ | +++ | +++ | – | – |
| E21BrD9 | Brain | CCR5 | – | +++ | +++ | – | – |
| E21BrD37 | Brain | CCR5 | +++ | +++ | +++ | – | – |
| E21BrD82 | Brain | CCR5 | +++ | +++ | +++ | – | – |
| E21BrD62 | Brain | CCR5 | +++ | +++ | +++ | – | – |
| E21BrD100 (R) | Brain | CCR5 | ++ | +++ | +++ | – | – |
| E21BrD107 (R) | Brain | CCR5 | ++ | + | +++ | – | – |
| KM34BlR14 | Blood | CCR5 | – | +++ | +++ | ++ | +++ |
| KM34BlR43 | Blood | CCR5 | + | ++ | +++ | – | – |
| KM34BlR52 | Blood | CCR5 | + | ++ | +++ | – | – |
| KM34BlR66 | Blood | CCR5 | – | ++ | – | – | +++ |
| KM34BlR70 | Blood | CCR5 | – | ++ | – | – | – |
| KM34BlR71 | Blood | CXCR4 | – | – | – | – | – |
| KM34SeR3 (R) | Semen | CCR5 | +++ | ++ | +++ | – | – |
| KM34SeR33 | Semen | CCR5 | +++ | +++ | +++ | – | – |
| KM34SeR63 (R) | Semen | CCR5 | – | +++ | +++ | – | – |
a
(R), characterized recombinant gp160.
b
Macrophage tropism is scored as follows: −, <1%; +, 1 to 5%; ++, 5 to 15%; and +++, >15% infectivity in HeLa TZM-BL cells. Maraviroc sensitivity (nM) is scored as follows: +++, IC50 = <0.25; ++, IC50 = 0.25 to 1.0; +, IC50 = >1; and −, CXCR4 user. sCD4, b12, and 2G12 sensitivity (μg/ml) is scored as follows: +++, IC50 = <10; ++, IC50 = 10 to 20; +, IC50 = 20 to 50; and −, >50.